Impact of degradable nanowires on long-term brain tissue responses by unknown
Gällentoft et al. J Nanobiotechnol  (2016) 14:64 
DOI 10.1186/s12951-016-0216-7
RESEARCH
Impact of degradable nanowires 
on long-term brain tissue responses
Lina Gällentoft1*, Lina M. E. Pettersson1, Nils Danielsen1, Jens Schouenborg1, Christelle N. Prinz1,2* 
and Cecilia Eriksson Linsmeier1*
Abstract 
Background: A promising approach to improve the performance of neural implants consists of adding nanomaterials, 
such as nanowires, to the surface of the implant. Nanostructured interfaces could improve the integration and commu-
nication stability, partly through the reduction of the cell-to-electrode distance. However, the safety issues of implanted 
nanowires in the brain need to be evaluated and understood before nanowires can be used on the surface of implants 
for long periods of time. To this end we here investigate whether implanted degradable nanowires offer any advantage 
over non-degradable nanowires in a long-term in vivo study (1 year) with respect to brain tissue responses.
Results: The tissue response after injection of degradable silicon oxide (SiOx)-coated gallium phosphide nanowires 
and biostable hafnium oxide-coated GaP nanowires into the rat striatum was compared. One year after nanowire 
injection, no significant difference in microglial or astrocytic response, as measured by staining for ED1 and glial 
fibrillary acidic protein, respectively, or in neuronal density, as measured by staining for NeuN, was found between 
degradable and biostable nanowires. Of the cells investigated, only microglia cells had engulfed the nanowires. The 
SiOx-coated nanowire residues were primarily seen in aggregated hypertrophic ED1-positive cells, possibly microglial 
cells that have fused to create multinucleated giant cells. Occasionally, degradable nanowires with an apparently 
intact shape were found inside single, small ED1-positive cells. The biostable nanowires were found intact in microglia 
cells of both phenotypes described.
Conclusion: The present study shows that the degradable nanowires remain at least partly in the brain over long 
time periods, i.e. 1 year; however, no obvious bio-safety issues for this degradable nanomaterial could be detected.
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Background
Micro- and nanostructured electrode surfaces have been 
suggested to improve recording properties and reduce 
tissue responses [1–7]. Thus, combining a nanostruc-
tured topography on a small, low-density and flexible 
interface, known to reduce glial scarring [8–10], opens 
up for the development of a new type of biocompatible 
neural interface, with potential to achieve high quality 
recordings from single neurons. One way of creating 
neural interfaces with nanostructured topography is to 
coat the electrode surface with nanowires [5, 11–15].
Cells have been shown to be able to grow and interact 
strongly with arrays of nanowires or nanopillars in vitro 
[13, 14, 16–20]. In particular, gallium phosphide (GaP) 
nanowire arrays have been shown to promote neurite 
outgrowth and reduce glial cell spreading [21, 22]. Previ-
ously, we have achieved successful acute in vivo record-
ings using neural interfaces with GaP nanowire surface 
modifications [15]. In order to test the biocompatibility 
of nanowires per se, we have recently investigated the 
brain tissue response to the injection of nanowires in the 
brain. In a first, relatively short-term nanosafety study, 
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we used 2  µm long GaP nanowires coated with silicon 
oxide (SiOx) and assessed the tissue response 1, 6 and 
12  weeks after injection [23]. One important finding 
of this study was that many, but not all, of the injected 
SiOx-coated nanowires had lost their structural integrity, 
i.e. both the GaP core and the SiOx coating were found 
to be degraded into fragments in vivo, within 12 weeks. 
The degraded nanowire fragments were found engulfed 
by macrophages/microglia in the injection tract [23], 
indicating that the nanowire material used could be frag-
mented or dissolved in the brain tissue but not cleared 
from the brain after 12 weeks.
However, it is unknown whether degradable nanowires 
will be completely removed from the injection site and 
eventually cleared from the brain over time. Importantly, 
it is also not known if degradable nanowires offer any 
advantage over non-degradable nanowires with regard to 
long-term inflammatory brain tissue response and neu-
ronal survival.
The purpose of the present study was thus to evaluate 
how degradable nanowires affect the long-term inflam-
matory brain tissue response and neuronal density and 
to compare with the effects of implanted non-degradable 
(i.e. biostable [24]) nanowires, which are known to persist 
in the brain for long periods of time [25]. Further aims 
were to investigate the possible persistence of nanowires 
or nanowire residues in the brain tissue after 1 year and 
to clarify which of the different brain cells, such as glial 
and neuronal cells engulf the nanowires or their residues.
To this end, we evaluated the brain tissue response to 
2  µm long degradable nanowires 1  year after injection. 
We compared the tissue response and neuronal sur-
vival in rat striatum after injections of degradable SiOx-
coated GaP nanowires (2  µm) to biostable, hafnium 
oxide (HfOx)-coated GaP nanowires (2  µm), dispersed 
in Hank’s balanced salt solution (HBSS). One year post 
injection, the neuronal loss and the inflammatory tissue 
response were evaluated by quantification of microglia/
macrophages, astrocytes, neuronal cell density, and total 
cell nuclei density, surrounding the nanowire injection 
site. The presence of nanowires and/or nanowire residues 
in cells and tissue was examined by detecting the scat-
tered laser light in a confocal microscope.
Methods
Nanowire growth and coating
Metal organic vapor phase epitaxy (MOVPE) (Aix 200/4, 
Aixtron, Germany) was used to grow GaP nanowires 
from 40  nm gold aerosol particles on (111)B GaP sub-
strates (Girmet Ltd, Moscow, Russia), as previously 
described [26]. The gold aerosol particles were randomly 
distributed at an average density of 1/µm2. The temper-
ature for nanowire growth was 470  °C. The nanowire 
growth was initiated by supplying trimethylgallium 
(Ga(CH3)3) in addition to phosphine (PH3). The growth 
time was adjusted in order to obtain a nanowire length 
of 2  μm. Precursor molar fractions were 4.3 ×  10−6 for 
Ga(CH3)3 and 8.5 × 10−2 for PH3. The hydrogen carrier 
gas flow was 6 L/min and the nanowire growth was con-
ducted under low pressure (10 kPa).
The GaP nanowires were coated with a 20  nm layer 
of SiOx using Atomic layer deposition (Fiji, Cambridge 
NanoTech Inc., USA). The nanowires were subsequently 
broken off from the substrate using ultra sonication and 
suspended in HBSS as vehicle solution to a final concen-
tration of 70,000 nanowires/µL.
The HfOx-coated nanowires were produced as 
described above except for the 20 nm HfOx atomic layer 
deposition, which was done using a Savannah-100 ALD 
system (Cambridge NanoTech Inc., USA), as published 
elsewhere [25].
Animals
Approvals for the animal experiments were obtained in 
advance from the Lund/Malmö local ethical committee 
on animal experiments (ethical permit number: M300-
10). Female Sprague–Dawley (SD) rats (Taconic, Den-
mark) were used. The rats were kept in a 12-h day-night 
cycle and received food and water ad  libitum. At the 
beginning of the experiment the rats weighed approxi-
mately 225  g and they followed a normal weight curve 
post surgery.
At the experimental start-point, 10 animals received 
striatal bilateral injections of 2  µm long degradable 
SiOx-coated nanowires suspended in HBSS [rats = 10, n 
(injections) = 20], for details see below. Two of the rats 
were killed before the predetermined 1  year end point 
of the experiment, in accordance with the ethical exclu-
sion criterion, since they developed age-related sponta-
neous tumors [25]. Furthermore, one rat was excluded 
since it did not meet our histological inclusion criteria. 
The results from the remaining seven rats (n = 14) were 
compared to data from our previously published study 
[25] where rats subjected to the same injection protocol, 
but injected with a suspension of 2 µm biostable HfOx-
coated nanowires (n = 11), were investigated. The reason 
to compare the results from the present study with those 
from an already published study was ethical, and done in 
order to minimize the number of animals subjected to 
surgery and subsequently kept for a whole year after the 
nanowire injections.
Surgery
The animals were anaesthetized by intraperitoneal (i.p.) 
injections of Fentanyl (0.3  mg/kg body weight) and 
Domitor vet (metedetomidin hydrochloride, 0.3  mg/
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kg body weight). The surgical area was shaved and the 
animal was positioned in a stereotactic frame (KOPF 
instruments, USA) under a stereomicroscope (Leica 
Microsystems, Germany). The scalp was disinfected 
using 70  % ethanol solution and local anaesthetic was 
administered, 0.25 % Marcaine (Bupivacaine, 0.33 mg/kg 
body weight) in sterile water. A 2 cm midline incision was 
made, connective tissue attached to the skull was care-
fully removed and blood was cleansed away. Under ste-
reotactic control bilateral craniotomies (approximately ø 
1 mm2) at 1.0 mm anterior and 2.5 mm lateral to bregma 
were drilled. Fine forceps were used to incise and deflect 
the dura mater, and stereotactic injections were made 
bilaterally using a 2  µL Hamilton syringe with a glass 
microcapillary (tip ø ~130 µm) attached. The HBSS sus-
pension with nanowires was injected into the striatum 
at two depths; 5  mm (1  µL) and an additional injection 
at 4 mm (1 µL), i.e. 2 µL/hemisphere over a total time of 
2 × 2 min.
The skin was closed with surgical clips. Before and 
after each session of nanowire injections, a drop of the 
nanowire suspension was ejected from the syringe onto 
a microscope slide and the presence of individually sus-
pended nanowires was confirmed using a Nikon eclipse 
80i microscope (Nikon, Japan).
After surgery, the animals were awakened under super-
vision. Subcutaneous injections of Temgesic (buprenor-
phine, 50  µg/kg body weight) were administered to 
reduce postoperative pain, as well as an antidote to the 
anaesthesia (Antisedan, atipamezole hydrochloride, 
0.5 mg/kg body weight).
Histology
The animals were killed by an i.p. overdose of pentobar-
bital 1  year post nanowire injection. The animals were 
transcardially perfused with  ~200  mL of ice-cold saline 
solution (sodium chloride 0.9  % in distilled water) fol-
lowed by  ~125  mL of ice-cold 4  % paraformaldehyde 
(PFA) in 0.1 M phosphate buffered saline (PBS) (pH 7.4). 
The brains were gently removed and following post-fix-
ation in 4  % PFA overnight (4  °C) they were cryo-pro-
tected in 25 % sucrose solution until equilibrated (4 °C). 
Cervical lymph nodes were also dissected and prepared 
for histology. The brains were snap frozen using dry ice 
and fixed to sectioning blocks using Tissue Tek optimal 
cutting temperature (O.C.T.) compound (Sakura Finetek, 
USA). Consecutive coronal sections were cut serially (6 
series) at 10 µm thickness onto Super Frost® plus slides 
(Menzel-Gläser, Germany) using a cryostat (Microm, 
Germany). The primary antibodies used to visualize acti-
vated microglia and macrophages [CD68 (ED1)], astro-
cytes [glial fibrillary acidic protein (GFAP)], and neuronal 
nuclei (NeuN) are summarized in Table  1. All stained 
sections were also counterstained using 4′,6-diamidino-
2-phenylindole (DAPI), which labels all cell nuclei. The 
tissue sections were hydrated and rinsed three times 
using PBS and as blocking solution, 5  % normal goat 
serum in 0.25  % Triton X-100 (Fluka/Sigma-Aldrich, 
Switzerland) in PBS, was used. Following incubation 
with blocking solution (1  h), the first series of sections 
was stained with ED1 and GFAP. The second series was 
stained with NeuN and additionally co-stained with 
GFAP in order to visualize the scar. The sections were 
incubated with primary antibodies (in blocking solution) 
at room temperature (RT) overnight. The following day, 
sections were rinsed in PBS (three times) and incubated 
with DAPI, goat anti-mouse IgG Alexa 488 and goat 
anti-rabbit IgG Alexa 594 (in blocking solution), in light 
sealed chambers, for 2  h at RT (Table  1). Subsequently, 
sections were rinsed three times with PBS and cover-
slipped using PVA-DABCO (polyvinyl alcohol, Fluka/
Sigma-Aldrich, Switzerland). For sections stained with 
NeuN (second series), an antigen retrieval protocol with 
a 10 mM sodium citrate buffer (0.05 % Tween 20, pH6) 
was performed, as previously described in Gällentoft 
et al. [25].
The cervical lymph nodes were sectioned and labeled 
with ED1 and DAPI according to the same protocol.
Image acquisition and analysis
A DS-Ri1 digital camera (Nikon, Japan) mounted on a 
Nikon eclipse 80i microscope (Nikon, Japan) with a 10× 
objective was used for image acquisition. The sections 
were screened for the scar using ED1- and GFAP-positive 
Table 1 List of primary antibodies, secondary antibodies and nucleic acid stain used in study
Name Characteristics Host Working dilution Source
ED1 (CD68) Activated microglia/macrophages Mouse 1:250 Cat. Nr. MCA341R, AbD Serotec, UK
GFAP Glial fibrillary acidic protein Rabbit 1:5000 Cat. Nr. Z0334, Dako, Denmark
NeuN Neuronal nuclei, neuronal marker Mouse 1:100 Cat. Nr. MAB377, Millipore, USA
Alexa Fluor 594 Goat anti-rabbit Goat 1:500 Cat. Nr. A11005, Invitrogen, USA
Alexa Fluor 488 Goat anti-mouse Goat 1:500 Cat. Nr. A11001, Invitrogen, USA
DAPI Nucleic acid stain (4′,6-diamidino-2-phenylindole) – 1:1000 Cat. Nr. D3571, Invitrogen, USA
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area. Where the scar was seen at its maximum, a pho-
tograph was taken of the fluorescence of the ED1- and 
GFAP-positive cells and cell nuclei (DAPI). These images 
were used for quantification of ED1, GFAP and DAPI. The 
adjacent brain sections in the second series were stained 
with the primary antibodies against NeuN and GFAP. 
These images were used for quantification of NeuN. A 
photograph of the fluorescence of GFAP-positive cells, 
NeuN-positive cells and cell nuclei (DAPI), was captured 
in the second series. The NIS-Elements 3.1 software 
(Nikon, Japan) was used for image capture and analysis. 
The quantification analysis was performed according to 
a previously described method [23, 25]. In short, a rec-
tangular shaped region of interest (ROI; total ROI area 
300 × 800 µm) was centred on the injection tract to evalu-
ate the tissue response. This area was divided into an inner 
ROI (100 × 800 µm) and an outer ROI (200 × 800 µm). 
The inner ROI was chosen to quantify the area 0–50 µm 
from the injection tract and the outer ROI to quantify the 
area 50–150 µm from the injection tract. The rationale to 
differentiate between these two regions is that neuronal 
activity can be recorded up to about 50 µm from an elec-
trode [27]. The outer ROI measures the possible wide-
spread tissue response radiating from the injection scar. 
The quantifications were carried out by measuring the 
proportion of immunoreactive area (for ED1 and GFAP) 
or by counting the number of cells (for NeuN and DAPI) 
within the total screened area, i.e. inner or outer ROI [23, 
25]. For ED1 and GFAP, intensity thresholds were set for 
each individual image and for each marker at a fixed mul-
tiplier of the mean background intensity. This was done in 
order to ensure that no unspecific staining was included 
in the area assigned as ED1 or GFAP-positive. Only the 
fraction of the area in the ROI above this set threshold 
was quantified. Intensity thresholds were set at 5.5 times 
the background intensity for ED1 immunofluorescence 
and at 4.5 times for GFAP immunofluorescence. Neu-
ronal nuclei density was quantified manually by counting 
the number of NeuN-positive cells (with a DAPI-positive 
nucleus) and cell nuclei density were quantified by count-
ing DAPI-positive nuclei (above ø 3 µm) within the ROIs.
In order to examine the presence (or absence) of 
nanowires in the tissue, we used confocal imaging. Con-
focal images of the scar were captured using a laser scan-
ning confocal microscope (Zeiss LSM 510, Germany) 
with a 63× oil-immersion objective (N.A. 1.4) and Zen 
software (Zeiss, Germany). Laser-reflection mode was 
used to visualize the nanowires within the sections. 
Image J was used for processing of the confocal images.
The cervical lymph nodes were scanned for presence 
of nanowires or residues of nanowires using confocal 
microscopy (scattered laser light mode).
Statistical analyses
SiOx-coated GaP nanowire injections, n = 14, were com-
pared to HfOx-coated GaP nanowire injections, n =  11 
(from a previous study [25]).
Mann–Whitney test was used for comparison of the 
two groups, P values  <0.05 (*) were considered signifi-
cant. Values within graphs are presented as median val-
ues with indication of the 25 and 75 percentiles and 
minimum and maximum values (boxplot). GraphPad 
Prism 6.0d software (GraphPad Software Inc., USA) was 
used to perform all analyses in the study.
The dataset supporting the conclusions of this article is 
included within the articles additional file (see Additional 
file 1).
Results
To determine the impact of degradable vs. biostable 
nanowire exposure on the brain tissue response, we 
injected 2 µm long SiOx-coated GaP nanowires into rat 
striatum. This was compared to the tissue response after 
injection of HfOx-coated 2 µm GaP nanowires. The dif-
ferent immunohistochemical markers were quantified 
in an inner and an outer ROI surrounding the injection 
tract, 1 year post nanowire injection.
Brain tissue response towards degradable vs. 
biostable nanowires after 1 year (inner ROI)
One-year post injection no significant differences were 
found for any of the markers examined, when compar-
ing the inner ROI (0–50  µm), in the two experimental 
groups. Boxplot graphs of the quantification in the inner 
ROI (a–d) and representative immunofluorescent images 
(e–f) are shown in Fig. 1.
For ED1, the median percentage of fluorescent area 
around the injection track of the SiOx-coated nanowires 
was 0.77  % (25 and 75  percentiles were 0.46 and 1.2  %, 
respectively), and 1.1 % (25 and 75 percentiles were 0.26 
and 1.5  %, respectively) for the HfOx-coated nanowires 
(Fig. 1a).
The median percentage of GFAP-fluorescent brain area 
for animals injected with SiOx-coated nanowires was 
15  % (25 and 75 percentiles were 12 and 27  %, respec-
tively), and 12  % (25 and 75 percentiles were 7.7 and 
20 %, respectively) for animals injected with HfOx-coated 
nanowires (Fig. 1b).
The median neuronal nuclei density, i.e. the num-
ber of neuronal nuclei (NeuN) per unit area in the 
inner ROI, was 8.0 ×  10−4 µm−2 (25 and 75 percentiles 
were 6.4 × 10−4   and 8.9 × 10−4 µm−2, respectively) for 
SiOx-coated nanowires and 7.5  ×  10−4  µm−2 (25 and 
75  percentiles were 5.9  ×  10−4 and 8.3  ×  10−4  µm−2, 
respectively) for HfOx-coated nanowires (Fig. 1c).
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Fig. 1 Inflammatory tissue response, cell nuclei and neuronal density (inner ROI). Quantification in the inner ROI (0–50 μm) of ED1-positive area 
(a), GFAP-positive area (b), NeuN density (c), and cell nuclei density (d) at 1 year for HfOx-coated GaP nanowires (biostable) and SiOx-coated GaP 
nanowires (degradable). The boxes correspond to median values with indication of the 25 and 75 percentiles, and the whiskers show the minimum 
and maximum values. Mann–Whitney test was used. Representative fluorescent images of the tissue response 1 year post injection of e 2 μm long 
HfOx-coated nanowires (biostable) and f 2 µm long SiOx-coated GaP nanowires (degradable). ED1-positive cells (green), GFAP-positive cells (red) 
and cell nuclei (blue). Scale bar 100 μm
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The total cell nuclei density (DAPI), i.e. the num-
ber of cell nuclei per unit area in the inner ROI was 
2.9 × 10−3 µm−2 (25 and 75 percentiles were 2.7 × 10−3 
and 3.1  ×  10−3  µm−2, respectively) for SiOx-coated 
nanowires and 3.0 ×  10−3  µm−2 (25 and 75  percentiles 
were 2.6 × 10−3 and 3.4 × 10−3, respectively) for HfOx-
coated nanowires (Fig. 1d).
Tissue response towards degradable vs. biostable 
nanowires at 1 year (outer ROI)
One year after injection no significant differences were 
found, for any of the markers used, when comparing the 
outer ROIs (50–150 µm) of the two experimental groups. 
Boxplot graphs of the quantification in the outer ROI 
(a–d) and representative immunofluorescent images 
(e–f) are shown in Fig. 2.
For ED1 the median percentage of fluorescent area, 
in the outer ROI, was 0.069  % (25 and 75  percentiles 
were 0.022 and 0.11  %, respectively) for SiOx-coated 
nanowires and 0.098 (25 and 75  percentiles were 0.058 
and 0.12  %, respectively) for HfOx-coated nanowires 
(Fig. 2a).
The median percentage of GFAP-fluorescent area was 
3.4 % (25 and 75 percentiles were 2.4 and 4.9 %, respec-
tively) for SiOx-coated nanowires and 3.9  % (25 and 
75 percentiles were 1.2 and 5.9 %, respectively) for HfOx-
coated nanowires (Fig. 2b).
The median neuronal nuclei density (NeuN) in the 
outer ROI, i.e. the number of neuronal nuclei per unit 
area was 1.3  ×  10−3  µm−2 (25 and 75  percentiles were 
1.2  ×  10−3 and 1.4  ×  10−3  µm−2, respectively) for 
SiOx-coated nanowires and 1.3  ×  10−3  µm−2 (25 and 
75  percentiles were 1.1  ×  10−3 and 1.5  ×  10−3  µm−2, 
respectively) for HfOx-coated nanowires (Fig. 2c).
The median nuclei density (DAPI) in the outer 
ROI, i.e. the number of cell nuclei per unit area, was 
2.7 × 10−3 µm−2 (25 and 75 percentiles were 2.5 × 10−3 
and 2.8  ×  10−3  µm−2, respectively) for SiOx-coated 
nanowires, and 2.7 ×  10−3 µm−2 (25 and 75 percentiles 
were 2.2 ×  10−3 and 3.1 ×  10−3 µm−2, respectively) for 
HfOx-coated nanowires (Fig. 2d).
Confocal examination of the tissue response 
towards SiOx‑coated (degradable) vs. HfOx‑coated 
(biostable) nanowires at 1 year
Using confocal microscopy (scattered laser light), we 
found that residual nanowire material from the SiOx-
coated GaP nanowires (and occasionally apparently 
intact nanowires) as well as intact HfOx-coated GaP 
nanowires engulfed by ED1-positive cells persisted in 
the tissue (Fig.  3). We could not detect any nanowires 
or nanowire residues in any other cell types investigated 
(neuronal cells or astrocytes).
Intact HfOx-coated nanowires were found in ED1-
positive cells, both in larger cell aggregates as well as 
in smaller ED1-positive cells (ø 5–10  µm) (Fig.  3a–e). 
For the degradable SiOx-coated nanowires (Fig.  3f–j), 
residues from nanowires were also detected inside ED1-
positive cells. However, these residues were primarily 
seen in aggregated hypertrophic ED1-positive cells (ø 
approximately ≥15  µm), possibly macrophages/micro-
glial cells that have fused to form multinucleated giant 
cells. SiOx-coated nanowires with an apparently intact 
shape were also found in the tissue, although, to a lesser 
extent, and primarily in single, smaller ED1-positive cells 
(ø 5–10  µm). These images also suggest that less mate-
rial remains at or in the vicinity of the injection site for 
the group receiving degradable SiOx-coated GaP nanow-
ires compared to HfOx-coated nanowires (Fig.  3a–j). 
Figure  4 shows merged close up laser scanning confo-
cal microscopy images of ED1-positive cells containing 
intact HfOx-coated nanowires (Fig. 4a) or residues from 
degraded SiOx-coated nanowires (Fig.  4b). The nanow-
ires are visualized in white inside microglia/macrophages 
using scattered laser light mode.
No nanowires or residues of nanowires were found in 
any of the cervical lymph nodes investigated.
Discussion
In this nanosafety study, we evaluated for the first time 
the long-term (corresponding to half the life time of the 
animal) impact of degradable nanowires on rat brain tis-
sue and compared to that of non-degradable nanowires. 
That both the core and the coating of the SiOx-coated 
GaP nanowires are degraded into fragments were con-
firmed using confocal microscopy images (Figs.  3, 4). 
Despite the difference in biostability between SiOx and 
HfOx coated GaP nanowires, the tissue response and 
neuronal density were not significantly different. More-
over, both residues from degradable nanowires and intact 
biostable nanowires remain engulfed in the microglia/
macrophages in the brain tissue 1  year post injection, 
indicating that clearance of nanoparticles from the brain 
is a very slow process.
The core material of the nanowires used in this study is 
GaP. GaP is a semiconductor and like many semiconduc-
tors, GaP has been shown to be susceptible to corrosion 
and degradation, a process that leads to a release of Ga 
ions [28]. We have previously evaluated the in  vivo soft 
tissue inflammatory response after implantation of GaP 
discs into the abdominal wall of rats [29]. In that study 
an increase of ED1-positive cells after GaP disc implan-
tation was found both in the reactive capsule and at the 
disc/tissue interface, possibly reflecting an increased 
local concentration of toxic Ga ions. In the same study, 
we also found elevated levels of Ga accumulated in blood, 
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Fig. 2 Inflammatory tissue response, cell nuclei and neuronal density (outer ROI). Quantification in the outer ROI (50–150 μm) of ED1-positive area 
(a), GFAP-positive area (b), NeuN density (c), and cell nuclei density (d) at 1 year for HfOx-coated GaP nanowires (biostable) and SiOx-coated GaP 
nanowires in vehicle solution (biostable). The boxes correspond to median values with indication of the 25 and 75 percentiles, and the whiskers 
show the minimum and maximum values. Mann–Whitney test was used. Representative fluorescent images of the tissue response 1 year post 
injection of e 2 μm long HfOx-coated nanowires (biostable) and f 2 µm long SiOx-coated GaP nanowires (degradable). Neuronal nuclei (green), 
GFAP-positive cells (red) and cell nuclei (blue). Scale bar 100 μm
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the inflammatory in vivo milieu both inside and outside 
of activated monocytes/microglia) at 37  °C [29]. These 
results have been confirmed by Richards et al. [28] using 
GaP wafers. Taken together, these results demonstrate 
that the GaP core of the nanowires used in this study 
degrades both in vitro and in vivo.
In another study we could not detect any sub-acute or 
neurotoxic effect for the degradable GaP nanowires in 
the brain 12 weeks after nanowire injection [23]. Further-
more, no gallium was detected in other tissues investi-
gated (blood, kidney and liver) using inductively coupled 
plasma sector field mass spectrometry (ICP-SFMS). This 
raised the question whether a possible continuous release 
of gallium from the nanowires locally in the brain could 
result in neurotoxicity when the exposure spans over 
a longer time period. Notably, in the present long-term 
study, we found no difference in the inflammatory tissue 
response (i.e. in ED1- or GFAP-positive cell area), in total 
cell nuclei density or neuronal nuclei density between the 
degradable and the biostable nanowire group 1 year post 
injection. Furthermore, we have previously shown that 
the brain tissue response seen 1 year after an injection of 
short biostable GaP nanowires is comparable to the brain 
tissue response seen after vehicle (HBSS only) injection 
[25]. Taken together, the degradable material does not 
result in any detectable neurotoxicity 1  year post injec-
tion. Note, however, that the amount of Ga introduced in 
the brain, in our degradable nanowire safety studies, are 
too low for measuring the amount of released Ga in the 
brain tissue using spectrographic methods (ICP-SFMS), 
as in Linsmeier et al. [29].
Feliu and colleagues [30], discuss if a biological envi-
ronment may impose hostile conditions to nanoparticles, 
and addresses the question whether inorganic nanopar-
ticles can be designed to be degradable in a controlled 
manner followed by clearance from the body via renal 
excretion. We have previously shown that GaP nanowires 
coated with 20 nm of SiOx were partially degraded after 
6 and 12 weeks and that residues were found engulfed by 
microglia [23]. Furthermore, Hwang et  al. [31], demon-
strated that silicon-based electronics could be dissolved 
Fig. 3 Confocal images 1 year post nanowire injection. Representa-
tive laser scanning confocal microscopy images of the scar area 
after injection of 2 μm long HfOx-coated (a–e) and SiOx-coated GaP 
(f–j) nanowires 1 year post injection. The intact HfOx-coated and 
fragmented SiOx-coated GaP nanowires are visualized in white using 
scattered laser light mode. The images demonstrate the difference in 
nanowire cell load and degradability of the two types of nanowires 
studied. Note also the few rod-shaped SiOx-coated nanowires found 
in single, small ED1-positive cells (arrows). ED1-positive cells (green), 
GFAP-positive cells (red), cell nuclei (blue) and nanowires (white, scat-
tered laser light). Scale bar 20 μm
◂
brain, liver and kidneys 12 weeks post implantation, con-
firming loss of Ga from the implanted GaP discs [29]. 
GaP is also dissolving in pure physiological saline as well 
as in hydrogen peroxide (H2O2, 0.1, 1, 10  %) (to mimic 
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under physiological conditions. These material dissolving 
properties are further demonstrated by Peled et al. [32], 
who reported a dissolution rate of ca. 2.15  nm/day for 
bare SiOx nanowires (20 nm in diameter) when exposed 
to PBS (37  °C) leading to non-continuous, segmented, 
nanowire structures after approximately 7–10  days of 
exposure. Similar dissolution rates was presented by 
Zhou et  al. [33], who showed that the SiOx nanowires 
(30  nm in diameter) exhibited dissolution after about 
10 days when exposed to PBS or Neurobasal neuron cell 
culture media (ThermoFisher Scientific, USA) which is a 
closer analog (than PBS) to an in vivo milieu. These stud-
ies further confirm that the GaP nanowire core as well as 
the SiOx-coating degrades and fragmentizes over time, 
thus, it might be expected that the SiOx-coated GaP 
nanowires would be completely dissolved in  vivo after 
1 year. We therefore hypothesized that the nanowire resi-
dues would be fully dissolved and cleared from the brain 
tissue after 1 year. However, the present data shows that 
nanowire residues and occasionally intact nanowires per-
sist in the brain, even after 1 year, suggesting that nano-
particle clearance from the brain, if it is taking place, is 
a very slow process. Indeed, we were not able to detect 
any nanowires or nanowire residue in the cervical lymph 
nodes, which is a known destination for emigrating 
monocytes [34]. This suggests that there is a very small or 
non-existing migration of microglia/monocytes loaded 
with degraded or intact nanowires to these lymph nodes, 
supporting the idea that nanoparticles in the brain might 
be eliminated in an extremely slow manner.
Our results could be compared to previous reports 
showing that nanoparticles can accumulate in the 
brain. For instance, Lee et al. [35], found that small col-
loidal silver (10 and 25 nm) nanoparticles remain in the 
brain tissue 4 months after oral delivery. Furthermore, 
van der Zande et  al. [36], found that polyvinylpyrro-
lidone-coated silver nanoparticles were not cleared 
from the brain, 84  days post-oral delivery. Kreyling 
et  al. [37], injected radiolabeled polymer-coated gold 
nanoparticles in the tail vein of rats and were able to 
measure radioactivity from both the core and shell in 
the brain already after 1 h. This might suggest that cer-
tain nanoparticles can pass the blood brain barrier into 
the brain and accumulate in the brain since the elimi-
nation of the nanoparticles appears to be a more com-
plex process.
When using confocal microscopy to compare acti-
vated microglial cells in the injection tract, we found a 
clear difference in microglial cell load comparing the two 
nanowire groups (Fig. 3). This suggests that some of the 
degraded material from the SiOx-coated nanowires have 
indeed been cleared from the injection tract or that the 
residue from the nanowires are degraded into very fine 
fragments, which might not be visualized using confo-
cal microscopy, since smaller debris scatter the light to 
a lesser degree. While there is an apparent difference 
in microglia load, there is as mentioned above, no sig-
nificant difference in the proportion of ED1-positive 
cell area when comparing the degradable and biostable 
nanowire groups. It may be speculated that degraded 
fragments or particles, due to their larger surface area 
as compared to biostable nanowires, provided an about 
equal effective stimulus to the microglia cells as that of 
biostable nanowires.
Fig. 4 Close-up confocal images. Merged close-up of laser scanning confocal microscopy images showing ED1-positive cells in the scar area after 
injection of 2 μm long HfOx-coated (a) and SiOx-coated GaP (b) nanowires 1 year post injection. The images show internalization of intact HfOx-
coated and degraded SiOx-coated GaP nanowires in microglia/macrophages. ED1-positive cells (green), GFAP-positive cells (red), cell nuclei (blue) 
and nanowires (white, scattered laser light). Scale bar 5 µm
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The degradable nanowires or residues from the degra-
dable nanowires were found only engulfed by ED1-
positive cells and were not found inside neurons or 
astrocytes. Interestingly, we found two phenotypes of 
activated ED1-positive microglia cells. One phenotype 
was the hypertrophic ED1-positive cells (ø approximately 
≥15  µm) that contained a load of residues from the 
degradable nanowires or of intact biostable nanowires. 
These hypertrophic cells were most often found in cell 
aggregations, possibly multinucleated giant cells. Occa-
sionally, intact biodegradable nanowires were detected 
in activated single, smaller sized ED1-positive cells (ø 
5–10 µm). It is possible, that the presence of nanowires 
in the brain tissue can give rise to formation of multinu-
cleated giant cells. These are highly activated cells, which 
produce large amounts of reactive oxygen species [38]. It 
might then be hypothesized that some of the ED1-posi-
tive cells, which engulf nanowires, fuse to become giant 
cells, which then might accelerate the breakdown of the 
degradable nanowires into fragments/residues. Hence, 
the finding that the SiOx-coated nanowires in the single, 
smaller ED1-positive cells appear to contain more intact 
nanowires as compared to the large ED1-positive cells 
or the aggregates of ED1-positive cells is consistent with 
this hypothesis.
In conclusion, we found engulfed intact nanowires 
and nanowire residues inside ED1-positive cells only. No 
obvious bio-safety issues or neurotoxicity were observed 
after injection of degradable 2  µm long GaP nanowires 
into rat striatum. Degradable nanowires with appar-
ently intact shape were rarely found in the brain. When 
degraded, both the coating and the core of the degradable 
nanowires were fragmented and the remnants were not 
cleared from the brain even 1 year post nanowire injec-
tion. We observed no advantage or disadvantage of using 
degradable nanowires as compared to biostable nanow-
ires in this long-term nanosafety study. It is important 
to mention that we can not exclude that other types of 
degradable materials could offer an advantage over bio-
stable nanobiomaterials in other experimental setups. 
However, we found that dissolution and removal of inor-
ganic material from the brain are very slow processes; 
these are very interesting findings which prompt for fur-
ther studies.
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